RU2016134751A - Соединения - Google Patents
Соединения Download PDFInfo
- Publication number
- RU2016134751A RU2016134751A RU2016134751A RU2016134751A RU2016134751A RU 2016134751 A RU2016134751 A RU 2016134751A RU 2016134751 A RU2016134751 A RU 2016134751A RU 2016134751 A RU2016134751 A RU 2016134751A RU 2016134751 A RU2016134751 A RU 2016134751A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- pharmaceutically acceptable
- formula
- acceptable salt
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/000140 | 2014-01-29 | ||
| CN2014000140 | 2014-01-29 | ||
| PCT/CN2015/000054 WO2015113451A1 (en) | 2014-01-29 | 2015-01-28 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016134751A true RU2016134751A (ru) | 2018-03-02 |
Family
ID=53756223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016134751A RU2016134751A (ru) | 2014-01-29 | 2015-01-28 | Соединения |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9815841B2 (esLanguage) |
| EP (1) | EP3099694B1 (esLanguage) |
| JP (1) | JP6474826B2 (esLanguage) |
| CN (1) | CN105980388B (esLanguage) |
| AU (2) | AU2015210554A1 (esLanguage) |
| CA (1) | CA2937430A1 (esLanguage) |
| ES (1) | ES2717757T3 (esLanguage) |
| RU (1) | RU2016134751A (esLanguage) |
| WO (1) | WO2015113451A1 (esLanguage) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201605342UA (en) | 2014-01-29 | 2016-08-30 | Glaxosmithkline Ip Dev Ltd | Compounds |
| US10913744B2 (en) * | 2015-02-13 | 2021-02-09 | Dana-Farber Cancer Institute, Inc. | LRRK2 inhibitors and methods of making and using the same |
| CN108934162A (zh) | 2015-12-16 | 2018-12-04 | 南方研究所 | 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法 |
| EP3573955A4 (en) | 2017-01-25 | 2020-08-05 | GlaxoSmithKline Intellectual Property Management Limited | COMPOUNDS TO INHIBIT KINASE LRRK2 ACTIVITY |
| CN110248936A (zh) * | 2017-01-25 | 2019-09-17 | 葛兰素史密斯克莱知识产权发展有限公司 | 化合物 |
| EP3587422A4 (en) * | 2017-02-22 | 2020-05-06 | Daegu-Gyeongbuk Medical Innovation Foundation | PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE |
| FI3604304T3 (fi) | 2017-03-23 | 2022-12-15 | Pyrrolopyridiinijohdannaisyhdiste, menetelmä sen valmistamiseksi ja sitä vaikuttavana ainesosana sisältävä farmaseuttinen koostumus proteiinikinaasiin liittyvien tautien ehkäisemiseksi tai hoitamiseksi | |
| JP2022523477A (ja) * | 2019-01-18 | 2022-04-25 | ボロノイ・カンパニー・リミテッド | ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物 |
| EP3915985A4 (en) | 2019-01-18 | 2022-09-28 | Voronoi Co., Ltd. | PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES |
| CZ308800B6 (cs) | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci |
| CA3135409A1 (en) | 2019-05-16 | 2020-11-19 | Dana-Farber Cancer Institute, Inc. | Pyrrolopyrimidine inhibitors of wild-type and mutant forms of lrrk2 |
| CN111205216B (zh) * | 2020-03-11 | 2022-03-29 | 连云港恒运药业有限公司 | 一种制备沙格列汀的方法 |
| AU2021371697B2 (en) * | 2020-10-29 | 2024-10-24 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| WO2022155419A1 (en) * | 2021-01-15 | 2022-07-21 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| AU2022246081A1 (en) | 2021-03-23 | 2023-10-12 | Halia Therapeutics, Inc. | Pyrimidine derivatives useful as lrrk2 kinase inhibitors |
| WO2023073013A1 (en) | 2021-10-27 | 2023-05-04 | H. Lundbeck A/S | Lrrk2 inhibitors |
| CN115108991B (zh) * | 2022-06-30 | 2023-05-05 | 南京理工大学 | 一种硝仿基吡唑起爆药及其制备方法 |
| US11958865B1 (en) | 2022-09-15 | 2024-04-16 | H. Lundbeck A/S | Leucine-rich repeat kinase 2 (LRRK2) inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004274403A1 (en) | 2003-09-03 | 2005-03-31 | Aventis Pharmaceuticals Inc. | 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| JP2009511527A (ja) * | 2005-10-13 | 2009-03-19 | グラクソ グループ リミテッド | Ｓｙｋ阻害物質としてのピロロピリミジン誘導体 |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US20090325964A1 (en) | 2008-05-23 | 2009-12-31 | Wyeth | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| ES2512727T3 (es) | 2009-09-29 | 2014-10-24 | Glaxo Group Limited | Nuevos compuestos |
| AU2011260323A1 (en) * | 2010-06-04 | 2012-11-15 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as LRRK2 modulators |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| WO2012045195A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| KR101566091B1 (ko) | 2010-11-10 | 2015-11-04 | 에프. 호프만-라 로슈 아게 | Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체 |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| AU2012244550C1 (en) * | 2011-04-21 | 2017-06-22 | Origenis Gmbh | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors |
| MD20140023A2 (ro) | 2011-09-22 | 2014-06-30 | Pfizer Inc. | Derivaţi de pirolpirimidină şi purină |
| WO2013079496A1 (en) | 2011-11-30 | 2013-06-06 | F. Hoffmann-La Roche Ag | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
| GB201204985D0 (en) * | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
| WO2013164323A1 (en) | 2012-05-03 | 2013-11-07 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
| CN104271569B (zh) | 2012-05-03 | 2016-08-24 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的吡唑氨基嘧啶衍生物 |
| EA025186B1 (ru) * | 2012-06-29 | 2016-11-30 | Пфайзер Инк. | НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2 |
| SG11201605342UA (en) | 2014-01-29 | 2016-08-30 | Glaxosmithkline Ip Dev Ltd | Compounds |
-
2015
- 2015-01-28 RU RU2016134751A patent/RU2016134751A/ru not_active Application Discontinuation
- 2015-01-28 JP JP2016549113A patent/JP6474826B2/ja not_active Expired - Fee Related
- 2015-01-28 EP EP15743645.2A patent/EP3099694B1/en active Active
- 2015-01-28 CN CN201580006294.1A patent/CN105980388B/zh not_active Expired - Fee Related
- 2015-01-28 ES ES15743645T patent/ES2717757T3/es active Active
- 2015-01-28 US US15/114,857 patent/US9815841B2/en not_active Expired - Fee Related
- 2015-01-28 CA CA2937430A patent/CA2937430A1/en not_active Abandoned
- 2015-01-28 WO PCT/CN2015/000054 patent/WO2015113451A1/en not_active Ceased
- 2015-01-28 AU AU2015210554A patent/AU2015210554A1/en not_active Abandoned
-
2018
- 2018-01-12 AU AU2018200271A patent/AU2018200271A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2717757T3 (es) | 2019-06-25 |
| AU2015210554A1 (en) | 2016-07-07 |
| US9815841B2 (en) | 2017-11-14 |
| JP2017504635A (ja) | 2017-02-09 |
| JP6474826B2 (ja) | 2019-02-27 |
| CA2937430A1 (en) | 2015-08-06 |
| CN105980388A (zh) | 2016-09-28 |
| AU2018200271A1 (en) | 2018-02-01 |
| WO2015113451A1 (en) | 2015-08-06 |
| EP3099694B1 (en) | 2019-01-16 |
| US20170022204A1 (en) | 2017-01-26 |
| EP3099694A4 (en) | 2017-06-14 |
| EP3099694A1 (en) | 2016-12-07 |
| CN105980388B (zh) | 2018-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504635A5 (esLanguage) | ||
| CY1123616T1 (el) | 7-βενζυλ-4-(4-(τριφθορομεθυλ)βενζυλ)-1,2,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(4η)-ονη, και αλατα αυτης και χρηση αυτων στη θεραπεια | |
| RU2020110780A (ru) | Ингибитор fgfr и его медицинское применение | |
| JP2014511892A5 (esLanguage) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| RU2018106453A (ru) | Соединения | |
| PH12020500265A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| JP2019517487A5 (esLanguage) | ||
| JP2016530283A5 (esLanguage) | ||
| JP2014514360A5 (esLanguage) | ||
| RU2015143542A (ru) | Ингибиторы jak2 и alk2 и способы их использования | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| EP4467549A3 (en) | Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives | |
| JP2014511891A5 (esLanguage) | ||
| JP2015537020A5 (esLanguage) | ||
| JP2016513661A5 (esLanguage) | ||
| EA201790088A1 (ru) | Ингибиторы syk | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2016515561A5 (esLanguage) | ||
| JP2014501766A5 (esLanguage) | ||
| AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
| RU2017105353A (ru) | Соединения | |
| JP2016503797A5 (esLanguage) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20180329 |